[ACC2011]Timothy D. Henry谈难治性心绞痛的细胞疗法
<International Circulation>:When stem cells are transplanted and developed into mature myocytes in vivo, what are the key factors involved?
《国际循环》:当干细胞被移植并在体内发展为成熟的心肌细胞,所涉及的关键因素是什么?
Dr Henry: One of the key things with cell therapy is people confuse what you are trying to do. For instance, people ask the question: Which cell is the best cell? That is like asking: Which antibiotic is the best antibiotic? One of the most important things is what are you trying to accomplish. With refractory angina, most of these patients have normal LV function so you don’t need new myocytes. What we are doing here is trying to improve blood vessels and blood supply by growing new blood vessels. This is distinctly different for refractory angina and for critical ischemia. What we need to do is promote angiogenesis. Now myogenesis, the growing of myocytes, is a much bigger and more challenging problem and related more specifically to heart failure.
Henry博士:细胞治疗的关键问题之一是人们会困惑于你正努力要做的事情。例如,人们会问这样的问题:哪种细胞是最好的?这就像是在问:哪种抗生素是好的?最重要的事情之一是你正在努力完成的事情。对顽固性心绞痛,大部分患者中左室功能正常,因此不需要新的心肌细胞。我们正在做的是通过增加新生血管来努力改善血管和血液供应。这对顽固性心绞痛和严重缺血具有重要意义。我们需要做的是促进血管生成。目前,肌细胞生成,即心肌细胞的生长,是一个更大的、更具挑战性的问题,对心力衰竭尤为重要。
上一页 [1] [2] [3] [4] 下一页